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Summary
Contrast-induced nephropathy (CIN) is an acute renal in-
jury due to the renal toxicity of iodinated contrast media.
It is classically defined as a relative (≥25%) or absolute
(≥0.5 mg/dl; 44 μmol/l) increase in serum creatinine from
baseline value. CIN accounts for 10 to 15% of hospital-ac-
quired acute renal failure and may rarely lead to irrevers-
ible renal function loss. Following percutaneous coronary
intervention, reported incidence of CIN varies between 0 to
24%, depending on the prevalence of risk factors and used
definition. Nowadays, the diagnosis of CIN relays on ser-
um creatinine monitoring, although, it is a late marker of
acute kidney injury. Given the expanding number of percu-
taneous coronary interventions made in outpatient settings
and the morbidity and mortality associated with CIN, early
detection of CIN is of utmost clinical relevance. Several
plasmatic and urinary biomarkers have been studied in that
view, with plasmatic cystatine-C and urinary NGAL be-
ing the most promising. As no treatment specifically tar-
gets CIN once it develops, the main goal for clinicians re-
mains prevention, with hydration status optimisation being
the only proven strategy to date.
Here, we will review the recent evidence concerning CIN
incidence, proposed early diagnostic biomarkers, as well as
its treatment and prognostic implication.
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Introduction
Contrast-induced nephropathy (CIN) is a decrease in glom-
erular filtration rate (GFR) following the injection of iod-
inated contrast media (CM). It is the third most common
cause of in-hospital acute renal failure (12%) after de-
creased renal perfusion (42%) and post-operative acute
renal failure (18%) [1]. Several routine diagnostic exam-
inations are CM-based and may therefore be complicated
by CIN. Reported incidence of CIN is 11% following out-
patient computed tomography [2], 9% after peripheral an-
giography [3], and 4% after intravenous pyelography [4].
When the vast majority of CIN cases still develop after
standard radiologic examinations, this complication may
also be increasingly encountered after percutaneous coron-
ary interventions (PCI) due to growing numbers of pro-
cedures, multiple comorbidities in patients undergoing PCI
and larger amounts of CM used for complex coronary le-
sions.
Functionally, CIN is considered an intrinsic acute kidney
injury (AKI), usually with conserved diuresis, but in severe
cases acute tubular necrosis and even end-stage renal dis-
ease may develop. As acute renal failure is associated with
disabling morbidity and mortality [5], prevention and early
detection of CIN are of utmost clinical relevance [6, 7].
Definition
After intravascular CM injection, immediate renal toxicity
may occur, and in most cases it remains fortunately free of
significant clinical consequences. However, renal function
can diminish and serum creatinine (SCr) may increase in
the following days. In absence of an universally accepted
definition [8], most authors define CIN as a relative
(≥25%) or an absolute (≥0.5 mg/dl = 44 μmol/l) increase in
SCr from baseline. In case of contrast-induced toxicity SCr
typically rises within the first 24–48 hours after exposition,
peaks at 3–5 days and returns near to baseline within 1–3
weeks [9]. How-ever, irreversible renal function losses oc-
cur in rare cases. Obviously, in addition to CM exposure,
the diagnosis of CIN requires (1.) a temporal relationship
between CM exposure and SCr elevation, and (2.) the ex-
clusion of an alternative cause to the acute renal failure.
Epidemiology and prognosis
When considering the largest randomised controlled trials
(n ≥250) addressing CIN following PCI during last 5 years,
protocol-defined CIN incidence ranges between <1% to
>20%, with an increased incidence after emergency PCI
[10–29].
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An increase in SCr post-PCI is associated with poorer out-
come regardless of initial renal function. In all-comers pa-
tients, even a mild increase in SCr (10–24% or 25–35
μmol/l) is linked to increased 30-day mortality (RR of 1.8
[CI 1.3–2.5]) [30] and, if patients suffering from acute
myocardial infarction are excluded, a post-PCI SCr eleva-
tion is even associated with a higher 1-year mortality than
periprocedural myonecrosis [31]. In a retrospective study
of 5967 all-comer patients with normal renal function un-
dergoing PCI, Lindsay and colleagues reported that both
the 1-year myocardial infarction rate (24.0% vs 11.6%,
p <0.005) and the 1-year mortality rate (9.5% vs 2.7%,
p <0.005) were significantly higher in those 208 patients
(3.5%) developing significant CIN. This trend was even
stronger in patients needing temporary dialysis (1.5% of
CIN patients) and remained significant after adjustment
for potentially confounding factors (age, diabetes, prior
myocardial infarction).[32] Similarly, in 439 patients with
chronic renal failure undergoing PCI, Gruberg and col-
leagues showed that 7% required transitory haemodialysis
and 0.9% were discharged on chronic dialysis. Among the
161 (37%) patients developing CIN, there was a 2 to 3-fold
increase in in-hospital (15% vs 5%, p = 0.001) and 1-year
mortality (35–45% vs 19%, p = 0.001) in comparison to pa-
tients without CIN [33].
Finally, in an attempt to stratify the prognosis of patients
who already developed CIN after PCI, Harjai and col-
leagues proposed a 3-level scoring system (grade 0 [SCr
<25% and <44 μmol/l], grade 1 [SCr ≥25% and <44 μmol/
l] and grade 2 [SCr ≥44 μmol/l]), and suggest that an in-
creasing grade is correlated with a worse long-term out-
come after PCI (6-month MACEs [12.4 vs 19.4 vs 28.6%,
p = 0.003]; 6-month all-cause mortality [10.2 vs 10.4 vs
40.9%, p <0.0001]; n = 985) [34].
Physiopathology of renal iodine
toxicity
CIN is a reduction in renal function consequent to the renal
toxicity of intravascular iodine contrast. The physiopatho-
logy of CIN is multifactorial and is still incompletely un-
Figure 1
Scheme of hypothesised pathways contributing to CIN
pathogenesis.
derstood. As shown in figure 1, at least five mechanisms
could contribute to its pathogenesis:
1. Direct toxicity of CM to tubular epithelial cells: CM
increase tubular osmolarity, as they are freely filtered
and not resorbed. Tubular cells exposed to high
osmotic load have been showed to suffer from
impairment in intracellular transport and energy
metabolism. They develop cytopathological changes
called “osmotic nephrosis”, ranging from tubular cell
vacuolisation to necrosis [35].
2. CM-induced alteration in renal microvascular
haemodynamics: Trials investigating modifications of
blood flow in renal arteries exposed to CM have
shown an initial increase in blood flow followed by a
sustained reduction.[36] This might be the result of (a)
a CM-induced increase in intratubular pressure leading
to a decrease in renal blood flow, (b) a direct
vasoconstrictor effect of CM on smooth muscle cells,
(c) an increased tubuloglomerular feedback due to
increased tubular osmolarity, and (d) CM-induced
release of several endogenous vasoconstrictors such as
adenosine and endothelin.[35] Blood flow reduction
unfortunately affects particularly the outer medulla,
which is particularly susceptible to ischaemia due to
its high metabolic activity [36]. Ischaemia is obviously
worsened by the impaired microvascular self-
regulation found in diabetic and hypertensive patients.
3. Reperfusion and reactive oxygen species toxicity:
Reactive oxygen species released by the subsequent
reperfusion also contribute to renal damages. As the
antioxidant reserve is decreased in elderly and the
baseline oxidative stress is increased with CKD or
diabetes, theses patients are especially vulnerable [36].
4. Toxicity due to inflammation: Similarly to other tissues,
renal parenchymal damages may be worsened by CM-
mediated complement cascade activation and
inflammatory cytokine release [36].
5. Toxicity due to tubular obstruction: Precipitation of
intratubular proteins induces by CM has been
proposed to contribute to CIN. However, CM failed to
precipitate Tamm-Horsfall protein in vitro and no
evidence support this theory in clinical trials [35, 36].
Similarly, although some trials report massive
precipitation of Bence-Jones protein in myeloma
patients, the risk is decreased with new generation CM
and hydration [35, 37, 38].
Therefore, the osmolarity as well as the viscosity and ionic
properties of CM are involved in nephrotoxicity. It should
finally be stressed that CIN remains an exclusion diagnosis
with only spare histopathological findings. Therefore, a
nontrivial proportion of “CIN”-labelled AKI might be of
different aetiology, such as due to cholesterol or throm-
boembolic emboli, peri-interventional- hypotension, or in-
terstitial nephritis due to different mechanisms.
Risk factors and risk assessment
Risk factors for CIN can be divided into patient-related
or intrinsic risk factors, and procedure-related or extrinsic
risk factors. Most prevalent intrinsic risk factors are pre-ex-
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istence of renal failure, concomitant hypotension, presen-
ce of congestive heart failure, older age, anaemia, diabetes
mellitus, and concomitant use of nephrotoxic drugs [6, 39,
40]. On the other hand, extrinsic risk factors comprise the
total amount and type of CM used, its route of administra-
tion (arterial versus venous) and the time period between
two (or iterative) CM expositions [41, 42].
To help clinicians to minimise or stratify the risk of CIN,
several score have been proposed. Mehran et al. compiled
a “simple risk score” illustrated in table 1 to predict CIN
occurrence after PCI, with weighted coefficients for inde-
pendent predictors of CIN. Risk 1 category (≤5 points) is
associated with a 7.5% risk of CIN and 0.04% risk of dia-
lysis; risk 2 category (6 to 10 points) with risks of 14% and
0.12%; risk 3 category (11 to 16 points) with risks of 26.1%
and 1.09%; and risk 4 category (≥16 points) with risks
57.3% and 12.6% respectively [40]. As it is known that
CM volume is an important factor for renal toxicity, oth-
er authors tried to determine a volume to risk correlation,
particularly in high-risk patients. In patients with CKD,
Brown and colleagues proposed the calculation of a “max-
imal allowable contrast dose” (MACD; contrast volume
limit [ml = 5 × body weight {kg}]/[88.4 × SCr {μmol/
l}]). Their results showed that patients receiving contrast
volumes exceeding the MACD were more likely to develop
CIN or to need dialysis (propensity-matched OR if exceed-
ing the MACD 1.75 [95%CI 1.49–2.07, p <0.001] and 3.13
[1.73–5.65, p <0.001] respectively) [43]. In patients with
ST-elevation myocardial infarction, Nymann et al. proved
that an adjustment of contrast amount to the eGFR allows a
reduction of the incidence of CIN [44].
Early diagnosis
CIN induces the same clinical and laboratory abnormalities
than other causes of acute renal failure. Most patients de-
veloping CIN are asymptomatic, but in severe cases they
become oliguric or anuric. Metabolic acidosis and hyper-
kalaemia are the most frequent laboratory findings, with
potential fatal consequences. Microscopic urine examina-
tion may show renal tubular cell casts and/or debrits as
well as urate and/or oxalate crystals. However, these find-
ings are not specific for CIN [45]. A persistent nephrogram
on radiograph or CT-scan has been studied for detection
of CIN [46], but its clinical relevance has not been valid-
ated. Therefore, the diagnosis of acute kidney injury (AKI)
relies on the monitoring of functional markers and/or bio-
markers in serum and urine. To improve patient manage-
ment, an ideal marker should be accurate and proportional
to renal injury, and have an early kinetic after renal dam-
age. Moreover it should help to differentiate acute struc-
tural damage (AKI) from functional impairment (prerenal
azotaemia) or chronic kidney disease (CKD). This is even
more important as intrinsic acute renal failure is grieved
with an increased risk of in-hospital mortality and/or need
for dialysis [47].
In daily practice, changes in SCr are used to estimate acute
modifications in renal function and SCr monitoring re-
mains the cornerstone for diagnosis of CIN. Unfortunately
creatinine is a late and insensitive indicator of acute
changes in renal function as there is a 24–48 hours delay
between renal insult and SCr changes [48].
Because of this pitfall and since an early diagnosis may de-
crease morbidity and improve patient survival [49], accur-
ate biomarkers are eagerly awaited for the early detection
of tubular dysfunction/lesion. In invasive cardiology, early
detection of CIN could allow a pre-discharge selection of
outpatients needing hospitalisation for closer renal, meta-
bolic and volaemic control. Recently, several promising
biomarkers of tubular insult have been under investigation
and the following plasmatic or urinary ones are of special
interest. Table 2 summarises some of their characteristics
relevant for the diagnosis of CIN.
Potential plasmatic biomarkers
Plasma Neutrophil Gelatinase-Associated Lipocalin
(NGAL or Lipocalin-2 [LCN2]).
NGAL is of particular interest in this setting and has been
considered as the “renal troponin” [50]. NGAL is a small
protein of the lipocalin superfamily that was first isolated in
1993 from the supernatant of activated human neutrophils
[7, 51]. It is also expressed and secreted by immune cells,
hepatocytes and renal tubular cells in various pathologic
states. Beside its bacteriostatic effects by transmembran-
ous iron shuttling, NGAL acts as a growth and differenti-
ation factor in multiple cell types, including renal epithelia,
where it limits apoptosis and contributes to maintain the tu-
bular structure [52]. NGAL is massively and rapidly upreg-
ulated in kidneys following an ischemic or nephrotoxic in-
jury, and is thought to participate in limiting parenchymal
damage [52, 53]. It is primarily synthesised in the ascend-
Table 1: Independent risk factors for Contrast-Induced Nephropathy (CIN) and calculation of Mehran simple risk-score.
CIN risk factors Mehran simple risk-score definition [40] Integer score
Systolic blood pressure <80 mm Hg for at least 1 h requiring inotropic support with medications or intra-aortic balloon
pump within 24 h of the procedure
5
Intra-aortic balloon pump within 24 h of the procedure 5
Decreased renal
perfusion
Congestive heart failure class III or IV by New York Heart association classification and/or pulmonary oedema 5
Older age Age >75 years 4
Anaemia Baseline haematocrit value <39% for men and <36% for women 3
Diabetes Present or not 3
Contrast media volume Absolute amount 1 for each 100 ml
Impaired baseline renal
function
Baseline serum creatinine >1.5 mg/dl
or
Baseline eGFR <60 ml/min
4
2 for 40–60
4 for 20–40
6 for <20
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ing loop of Henle and in collecting ducts but has also neph-
roprotective effects in the proximal tubule [52]. NGAL –
as marker of AKI – is increasingly studied since its serum
and urinary levels increase well before the increase of SCr
[54] and have a better sensitivity than SCr alone for acute
kidney injury detection [48]. More specifically, plasma and
urine NGAL levels are also known to be powerful inde-
pendent predictors of CIN, in-hospital outcomes, and risk
for dialysis or death [7, 48, 55]. However, despite being
considered as a promising biomarker for early diagnosis
of acute tubular necrosis by several authors [56], plasma
NGAL (pNGAL) is less specific than its urinary counter-
part. In fact, pNGAL is already increased in patients with
CKD [53] or systemic illnesses [52], and increases 6-times
less than urinary NGAL in case of renal injury [52].
Plasma cystatine C (CysC)
CysC is produced at a constant rate by all nucleated cells.
Under normal circumstances, it is freely filtered by the
glomeruli and totally reabsorbed in the proximal tubule. In
the absence of tubular dysfunction, its serum level reflects
glomerular filtration and can be used as a functional mark-
er for acute and chronic changes in GFR [57]. In intens-
ive care settings, plasma cystatine C (pCysC) was able to
detect AKI earlier and was more sensitive than SCr in de-
tecting minor glomerular filtration rate reductions [58, 59].
This early increase of pCysC following a renal insult is also
reported in trials addressing renal CM toxicity [60, 61]. In
CKD patients, a >10% increase in pCysC 24 hours after
PCI predicts CIN (as defined by a >0.3 mg/dL increase in
SCr) with a sensitivity of 100% and a specificity of 86% (n
= 410) [62]. Unfortunately, pCysC levels may also be in-
fluenced by several non-renal factors including corticoster-
oids administration, thyroid dysfunction, systemic inflam-
mation, neoplasia, age and eventually muscular mass [57].
Potential urinary biomarkers
Urinary Neutrophil Gelatinase-Associated Lipocalin
(NGAL or Lipocalin-2 [LCN2])
Urinary NGAL (uNGAL) is increased in case of AKI and
remains low in patients with prerenal azotaemia or normal
renal function [49, 63]. To note, less than 0.2% of tagged
NGAL injected in the circulation appears in urine during
the first hour [64]. uNGAL is of interest for the early dia-
gnosis of CIN, as it increases already 2 hours after tubular
injury [54]. Haase M. et al. analysed data from 191 patients
in 3 studies and found that when uNGAL is measured with-
in 6 hours after CM exposition, the sensitivity is 0.78, the
specificity is 0.96, and the area under the receiver operat-
ing characteristic (ROC) curve is 0.89 for the diagnosis of
CIN (cut-off for uNGAL: 100 ng/ml) [56].
Urinary interleukin-18 (IL-18, interferon-gamma-inducing
factor)
In 2004, Parikh and colleagues demonstrated that patients
with acute tubular necrosis had significantly greater medi-
an urinary IL-18 (uIL-18) concentrations than those with
other renal conditions (normal renal function, pre-renal
azotaemia, urinary tract infection, and chronic renal insuf-
ficiency). Therefore, they proposed it as a specific bio-
marker of proximal acute tubular necrosis [65]. More re-
cently, the same group showed in patients undergoing car-
diac surgery that increased uIL-18 levels were associated
with AKI, longer hospital stay and higher risk for dialysis
or death (cut-off: 60 pg/ml) [55]. On the other hand, 24
hours after PCI uIL-18 levels are significantly increased
in patients developing CIN compared to controls, reducing
the diagnostic delay by 24 hours [66].
Urinary liver-type fatty acid-binding protein (L-FABP)
L-FABP is a cytoplasmic protein that facilitates the long-
chain fatty acid transport from the plasma membrane to
beta-oxidation sites and reduces the oxidative stress by
binding of fatty acid oxidation products [67]. Its urinary
levels are significantly elevated in patients with AKI [67,
68]. This biomarker is of particular interest as a sensitive
and predictive early biomarker of AKI, but it might have a
low specificity due to interferences with different system-
ic processes regularly found in critically-ill patients [67].
Interestingly, according to the study by Nakamura and col-
leagues (n = 66), even pre-PCI urinary L-FABP levels pre-
dict CIN [69].
Urinary kidney injury molecule-1 (KIM-1)
KIM-1 is a transmembranous protein normally not detect-
able in urine, but expressed at very high levels in proximal
tubular epithelial cells soon after an ischemic or toxic in-
jury [70]. Han and colleagues report that urinary KIM-1
is able to rapidly detect AKI [70], with higher levels for
“pure” ischaemic insult than for other types of acute renal
failure [71]. Since the pathogenesis of CIN is multifactori-
al, the use of this biomarker seems limited in this particular
context [71, 72].
Urinary N-Acetyl-β-glucosaminidase (β-NAG)
β-NAG is a lysosomal enzyme found mainly in proximal
tubular cells that is a sensitive marker of proximal tubular
injury from various aetiologies [70]. Compared with SCr,
urinary β-NAG peaks earlier [73]. However, its discrimat-
Table 2: Relevant characteristics of biomarkers for the diagnosis of CIN after PCI.
Biomarker■* Molecular weight (kDa) Site of lesion Significant increase in CIN-patients AUC for CIN-prediction (cut-off)
pNGAL 25 Distal and collector tubules 2 hours [111] 0.92 (≥100 ng/ml at 2 hours) [112]
pCysC 13 Glomeruli and proximal tubule 8 hours [111] 0.92 (≥10% increase at 24 hours) [62]
uNGAL 25 Distal and collector tubule 2 hours [111] 0.92 (≥100 ng/ml at 2 hours) [112]
uIL-18 18 Distal tubule 8 hours [111] 0.75 (≥25% increase at 24 hours) [66]
uL-FABP 14 Proximal tubule 24 hours [111] NA
uβNAG 130 Proximal tubule 24 hours [73] NA
* ■; βNAG = n-acetyl-β-glucosaminidase; CysC = cystatin C; IL-18 = interleukin 18; L-FABP = liver fatty acid-binding protein; NGAL = neutrophil gelatinase-associated
lipocalin; p = plasma; u = urinary.
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ive power seems insufficient to allow clinical use for AKI
diagnosis [63].
Prevention and therapy of CIN
Patients developing CIN should receive similar supportive
care as every patient with acute renal failure: monitoring
and correction of serum electrolytes abnormalities and
metabolic acidosis, and tight control of fluid balance.
Therefore, as no treatment specifically targets CIN, the
main goal for clinicians remains prevention and support.
Table 3 summarises the main preventive guidelines. First
of all, some general considerations should be kept in mind:
the indication for contrast-based procedures should always
be pondered carefully and outweighed against the potential
risk of CIN. Then, whenever possible, concomitant nephro-
toxic drugs such as non-steroidal anti-inflammatory drug,
nephrotoxic antibiotics or chemotherapeutic agents and/or
iterative exposition to CM should be avoided.
Contrast media (CM)
The type and amount of contrast medium impact on the risk
of CIN. Briefly, all iodine CM consist in ≥1 benzene ring
linked to three iodine atoms. Three generations have been
described according to the osmolality. The first-generation
contrast agents (iothalamate, diatrizoate, metrizoate) are
composed of iodinated ionic monomers and are considered
“ionic high osmolar” (about 2000 mOsm/l), as an ioniz-
ing carboxyl group dissociates in solution. The second-
generation contrast agents (iohexol, ioversol, iopromide,
iomeprol, iopamidol), called “low-osmolar“, are nonionic
monomers with intermediate osmolality. Finally, the last
generation of contrast agents (iodixanol) are dimers of two
benzene rings and are virtually “iso-osmolar” in compar-
ison to plasma (290 mOsm/l) [8, 74]. It is considered that
osmolality per se contributes to the reported difference
in CIN incidence, with lessened osmotic load and tubular
work for last-generation CM [75, 76]. In a meta-analysis
Barrett et al. concluded that the incidence of CIN is sig-
nificantly reduced by use of “low-osmolar” compared to
“ionic high-osmolar” CM only among patients with pre-ex-
isting CKD [77]. In addition, From et al. report that “iso-
osmolar” agents shows a significant benefit when com-
pared to iohexol but not in comparison to other “low-
osmolar” CM [78]. However, “high-osmolar ionic” CM
have progressively been replaced by “low or iso-osmolar”
agents in current routine practice.
As discussed previously, the volume of the CM used also
contributes to the risk of renal toxicity. Therefore, in high-
risk patients and even more in patients with pre-existing
renal failure or diabetes, the CM volume should be limited
as much as possible and, in example, levography done only
if echocardiographic measurement is not possible.
Hydration
Hydration is the best-proven way to prevent CIN [13, 79].
Isotonic normal saline (NaCl 0.9%) is routinely used. The
use of sodium bicarbonate (NaBic 1.4% or NaHCO3 154
to 166 mEq/l) is also of interest since it reduces the produc-
tion of free radicals by decreasing tubular acidity and scav-
enges the oxidant pernitrite [80]. Individual results from
trials comparing normal saline (NaCl 0.9%) to sodium bi-
carbonate (154 mEq/l in dextrose 5%) gave contradictory
results [12, 13, 17, 19, 21, 22], but a recent meta-analysis
by Kunadian et al. favours the use of sodium bicarbonate
[80].
Hydration is usually performed using a peripheral line,
with a classical infusion rate of 1 ml/kg/h during 12 hours
before and after PCI. To note, the pre-PCI hydration can be
replaced by a rapid one-hour perfusion (3 ml/kg) in emer-
gency situations. Using a combination of oral volume sup-
plementation and intravenous isotonic or half-isotonic in-
fusion at a rate of 1 ml/kg/h between 8 a.m. the day of
procedure and 8 a.m. the following morning, Mueller and
colleagues reported a CIN-incidence (≥0.5 mg/dl increase
in SCr within 48 hours of procedure) as low as 1.4% after
PCI in a Swiss cohort of 425 consecutive patients (mean
baseline eGFR: 89 ml/min). Even in the subgroup of pa-
tients with eGFR ≤60 ml/min (n = 43), the incidence of
CIN remained low (4.7%), with no patient requiring dialys-
is [81].
To maintain an optimal hydration status and a high urinary
output (≥300 ml/h), while minimising the risk of pulmon-
ary edema, Briguori et al. proposed the use of the Ren-
alGuard System, which matches urinary output with in-
travenous hydration and furosemide administration. The
nephro-protective effect of this system may be due to an
increased urine output diluting the tubular CM, and to the
blockade of the Na-K-2Cl co-transporter, decreasing the
oxygen consumption of tubular cells. Briguori et al.
showed that the use of the RenalGuard System with normal
saline hydration in high-risk patients (eGFR ≤30 ml/min
and/or Mehran risk score ≥11 points) significantly de-
creases the incidence of CIN (2.7%), when compared to
usual hydration with sodium bicarbonate (13%; p = 0.001)
[82]. Although the hydration solution was different in both
groups, the nephron-protective effect of the RenalGuard
system was already shown with use of normal saline in
both control and RenalGuard groups by Bartorelli et al.
[83]. Finally it is worth noting that patients treated with
Table 3: Prevention of CIN (based on references [39, 113, 114]).
Clinicians should:
1. Be aware that CIN is a potentially serious complication.
2. Ponder the risk and benefit of any CM-based exam.
3. Optimise hydration status with oral and intravenous fluids.
4. Stop concomitant nephrotoxic medications (diuretics, NSAIDs, chemotherapy).
5. Use only new generation CM.
6. Use the lowest amount of CM.
7. Monitor SCr at 24–72 hours after CM-exposition, at least in high-risk patients.
8. Try keeping 1 week interval between 2 CM-based exams.
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the RenalGuard System had no increased risk of peripro-
cedural pulmonary edema or electrolyte imbalance [82].
However, , even if RenalGard gated hydration seems to be
a promising tool for prevention of CIN, one should not for-
get the difficulty of its use in emergency settings and the
risk of urinary tract infection brought by ureteral cathet-
erisation.
Nephroprotective drugs
N-acetylcysteine (NAC)
The prophylactic use of NAC is under debate. Being a pre-
cursor for glutathione synthesis, NAC has the potential to
diminish oxidative stress by directly scavenging superox-
ide radicals and increasing intracellular glutathione. In ad-
dition, NAC improves renal haemodynamics by combin-
ing and stabilising bioavailable nitric oxide [10, 84, 85].
However, since the first positive study addressing NAC for
the prophylaxis of CIN in 2000 [86], several trials have
given discordant results [10, 27, 87, 88]. The recently pub-
lished Randomised Acetylcysteine for Contrast-Induced
Nephropathy Trial (ACT) addressing 2308 patients with at
least 1 risk factor for CIN undergoing coronary or peripher-
al angiography fails to show a beneficial effect of high-
dose NAC on CIN-incidence (12.7%) or other composite
outcomes. Even subgroups analysis, for example in pa-
tients with pre-existing kidney disease or diabetes, does not
show a significant benefit of NAC [10].
Statins
Beside their hypolipaemic role, statins improve endothelial
function and decrease oxidative stress and inflammation
[89]. In a review by Zhang and colleagues, chronic statin
treatment (≥1 week) reduces the risk of CIN (p <0.05),
whereas a short-term high-dose therapy does not [89].
These results have to be interpreted cautiously due to het-
erogeneity in statin regimens (drug used, doses and dura-
tion of therapy) and in procedural characteristics [90–92].
Vasoactive drugs
As contrast administration elicits an afferent arteriolar
vasoconstriction that decreases renal blood flow and glom-
erular filtration rate, several vasoactive treatments have
been studied in small collectives with some encouraging
results.
Prostaglandin E1
Prostaglandin E1 (PGE1) is a well-known vasodilator that
improves renal blood flow. A 20 ng/kg/min PGE1 infusion
has a significant protective effect on post-PCI SCr eleva-
tion [93, 94], but higher infusion rates are not associated
with increased benefits, probably due to the associated de-
crease in systemic blood pressure [93].
Dopamine
“Low-dose” or “renal-dose” dopamine (0.5–2.5 μg/kg/min)
has also been proposed for CIN prevention as it (1.) in-
creases renal plasma flow and glomerular filtration rate via
a dilatory effect on renal vasculature, (2.) improves tubular
function and (3.) increases cardiac output [95]. However,
neither Gare et al. nor Abizaid et al. show any significant
beneficial effect of dopamine for CIN-incidence reduction
in CKD patients [95, 96].
Fenoldopam mesylate
Fenoldopam mesylate is a specific dopamine-1 receptor ag-
onist that selectively increases both the renal cortical and
outer medullary blood flow while decreasing systemic vas-
cular resistance. Unfortunately it also fails to reduce CIN-
incidence in CKD patients [97, 98]. To note, some ded-
icated catheters, such as the Benephit system, have been
designed in order to deliver per-procedural protective treat-
ments directly into the kidney arteries. In a retrospective
serie of 285 patients, Weisz et al. reported a 71% decreased
in CIN incidence with local fenoldopam therapy (0.05–0.8
µg/kg/min) [99].
Theophylline
Adenosine is a vasoactive mediator which levels increase
secondary to oxygen consumption or decreased intracellu-
lar ATP and contributes to afferent arteriolar vasoconstric-
tion in kidneys following CM-exposure. The clinical be-
nefit of the competitive adenosine antagonist theophylline
is debated. Erley and colleagues reported that theophylline
administration prevents a post-PCI fall in GFR measured
by inuline clearance during the 4 post-procedural hours
[100]. However other groups found no significant protect-
ive effect of theophylline on renal function [88, 96, 100,
101].
Calcium channel inhibitors
It has been shown that calcium channel inhibitors antagon-
ise pre-glomerular vasoconstriction in dogs [102] and pre-
vent increases in intracellular calcium concentrations in an-
oxic animal cell culture [103]. However, their short-term
use for CIN prevention yielded various results: only one tri-
al showed benefit of initiating a calcium inhibitor treatment
shortly before PCI [104], while the others did not [105,
106].
Angiotensin-converting enzyme inhibitors
Angiotensin-converting enzyme inhibitors (ACEIs) play an
important role in treating heart disease and some of its risk
factors. Angiotensine-II acts on renal micovascular haemo-
dynamic homeostasis by inducing efferent arteriolar vaso-
constriction. As ACEI are known for decreasing GFR, sev-
eral groups have addressed their role in CIN. In a recent
review, Patel and colleagues found conflicting results of the
short- and long-term ACEI use on CIN-incidence, even in
high-risk patients [107]. On the other hand, pre-procedural
withholding of long-term (≥1 month) ACEI or ARB ther-
apy in patients with stage III-IV CKD undergoing elective
PCA has shown no beneficial effect on SCr levels meas-
ured one day after contrast medium exposure [24].
Conclusions
In view of these elements, several unresolved questions
remain concerning the management of CIN. First of all,
CIN is usually an asymptomatic complication, which dia-
gnosis relies on SCr increase following CM exposition,
but without clear-cut diagnostic criteria. Second, the
physiopathology of CIN is multifactorial and still incom-
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pletely understood, making it hard to improve diagnostic
and therapeutic tools. Third, the comparison of CIN-incid-
ence between trials is matter of caution, as CIN defini-
tions and prevalence of risk factors are often quite different
among the studies. However, once the contributing vari-
ables are taken into account, it appears that in the era of
modern contrast media, CIN remains, fortunately, revers-
ible in most cases. Even in patients with risk factors such as
CKD or diabetes, the risk of dialysis-dependent end-stage
renal disease due to CIN remains low (<1%). It is import-
ant to note that although gadolinium has been proposed as
CM for angiography in high-risk patients for CIN, its use
is grieved with the risk of development of nephrogenic sys-
temic fibrosis (NSF) in CKD patients, especially those with
eGFR ≤30 ml/min or dialysis-dependent [108]. In CKD pa-
tients, the incidence of NSF could even exceed the risk of
CIN, as some series show the incidence to be as high as
5% [109, 110]. As there is no available treatment to stop
the chronic progressive course of the disease resulting in
variable organ damage (skin, joints, lungs, kidneys…) and
leading to death, the European Society of Urogenital Radi-
ology does not recommend the use of gadolinium to avoid
the nephrotoxicity associated with iodinated CM [108].
As no treatment specifically targets CIN once it develops,
the main goal for clinicians remains prevention. They can
use several scores to carefully estimate the risk of CIN be-
fore referring a patient for elective PCI, particularly for
high-risk patients and/or procedures. Once decision for
CM-injection is made, clinicians have only 2 proven ways
to reduce the incidence of CIN: (1.) optimal hydration –
with some data favouring the use of sodium bicarbonate
over normal saline – and (2.) the use of lowest amount of
CM. To date, N-acetylcysteine, as well as all other drugs,
failed to confirm any beneficial preventive effect in large-
scale randomised studies.
In current practice, the standard method for renal function
monitoring remains SCr, although it is late and insensitive.
As the number of PCI made on outpatient basis grows,
there is an urgent need for tools allowing an early and ac-
curate detection of CIN. In this regard urinary NGAL and
plasma cystatin C seem to be the most promising. Permit-
ting closer renal function monitoring after CM exposure,
these early biomarkers will also help developing new pre-
ventive and/or therapeutic methods for the management of
CIN. However, in view of the very rare long-term conse-
quences of CIN after PCI, and as long as no specific treat-
ment targets CIN, we recommend the use of theses costly
biomarkers only for selected patients.
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Figures (large format)
Figure 1
Scheme of hypothesised pathways contributing to CIN pathogenesis.
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